Less Ads, More Data, More Tools Register for FREE

Regulatory News

Tuesday, 23 June 2026
RNS

Want to keep even more up to date with live RNS alerts?

Register for FREE
TimeSourceTIDMHeadline
7:00 amRNSGPMTransaction in Own Shares
7:00 amRNSTRIGTransaction in Own Shares
7:00 amRNSRCPTransaction in Own Shares
7:00 amRNSEXPNTransaction in Own Shares
7:00 amRNSGLBTransaction in Own Shares
7:00 amRNSCLBSTransaction in Own Shares
7:00 amRNSJEGIFinal Results
7:00 amRNSGMRTransaction in Own Shares
7:00 amRNSVOFTransaction in Own Shares
7:00 amRNSCRETransaction in Own Shares
7:00 amRNSHVPETransaction in Own Shares
7:00 amRNSBIGAGM Statement
7:00 amRNSAAFTransaction in Own Shares
7:00 amRNSEDINTransaction in Own Shares
7:00 amRNSCLDNTransaction in Own Shares
7:00 amRNSJDWTransaction in Own Shares
7:00 amRNSGAMATransaction in Own Shares
7:00 amRNSHERCAGM Statement
7:00 amRNSEMANExercise of Options and Total Voting Rights
7:00 amRNSJSGTransaction in Own Shares
7:00 amRNSKLRTransaction in Own Shares
7:00 amRNSQQ.Transaction in Own Shares
7:00 amRNSAVAPTransaction in Own Shares
7:00 amRNSCCTAdoption of an EMI share option scheme
7:00 amRNSDKLBond Refinance – First Tranche Completion
7:00 amRNSRKWIssue of Equity and TVR
7:00 amRNSMCBTransaction in Own Shares
7:00 amRNSLMPConfirmation of post-offer intentions re. SHED
7:00 amRNSFEVRTransaction in Own Shares
7:00 amMFN Attendo: Repurchases of shares during week 25, 2026
7:00 amMFN0GFEEmbracer Group: Buyback of B shares in Embracer Group during week 25, 2026
7:00 amPRNRHRDirector/PDMR Shareholding
7:00 amPRNBRGETotal Voting Rights
7:00 amPRNSUNBTransaction in Own Shares
7:00 amPRNBRSCTotal Voting Rights
7:00 amPRNCAKDPayment of Dividends
7:00 amPRNACRMResult of Oversubscribed Retail Offer
7:00 amMFN Castellum: Threshold exceeded for major shareholding notification due to repurchases of own shares
7:00 amGNWNBPENBPE Announces Transaction in Own Shares
6:00 am
6:15 amGNW Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
6:00 amPRN Start of Day
6:00 amGNW Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
6:00 amGNW Start of Day Message
5:00 am
5:00 amRNS Service Notice
5:00 amRNS Test Message

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.